A Reynolds American subsidiary donated $5 million to a super PAC supporting President Donald Trump on April 30. Two days later, tobacco industry executives met with Trump at his golf club in Jupiter, Florida, to complain about federal regulation of vaping products. Less than a week after that meeting, the Food and Drug Administration issued new guidance that could help major cigarette manufacturers expand into the flavored vape market and sell nicotine products with higher nicotine levels. The sequence of events has fueled renewed scrutiny over the relationship between political donations, corporate access, and federal policymaking, particularly as the Trump administration continues to roll back regulations affecting industries that have invested heavily in the president’s political operation.
The donation, disclosed in a campaign finance filing, came through a Reynolds subsidiary and increased its total contributions to MAGA Inc., the Trump-backed super PAC, to $8 million. Reynolds, the company behind Camel and Lucky Strike cigarettes, has become one of several major tobacco interests maintaining close financial ties to Trump and his political allies. According to campaign finance records cited in recent reporting, the same subsidiary previously contributed $10 million to another super PAC supporting Trump’s presidential campaign. Reynolds also contributed to fundraising efforts connected to Trump’s planned White House ballroom project, and a company executive was invited to a White House donor dinner reserved for individuals who had contributed at least $2.5 million.
The timing of the latest donation attracted attention because it was immediately followed by direct engagement between tobacco executives and the president. At the May 2 gathering in Florida, representatives from Reynolds and Altria, the parent company of Philip Morris and Marlboro, reportedly expressed frustration with the FDA’s oversight of e-cigarettes and nicotine products. According to people briefed on the meeting, Trump interrupted the discussion and attempted to call FDA Commissioner Marty Makary. When Makary did not answer, Trump reportedly contacted Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz, complaining about the FDA’s approach to vaping regulation.
Within days, the administration unveiled a regulatory shift that could significantly benefit the tobacco industry. The FDA issued new guidance that could pave the way for major cigarette manufacturers to enter the flavored vape market, a sector that has become increasingly important as traditional cigarette sales continue to decline. The agency also authorized mango and blueberry flavored vaping products sold by the Los Angeles-based company Glas Inc., a decision viewed by industry observers as a possible opening for larger tobacco companies to pursue similar approvals. At the same time, the guidance signaled that higher nicotine levels could be permitted in nicotine pouches, products that have become increasingly popular among nicotine users seeking alternatives to cigarettes.
The policy represented a substantial departure from years of regulatory efforts aimed at reducing youth nicotine consumption. Federal health officials have long argued that flavored vaping products play a major role in attracting younger users. According to a Centers for Disease Control and Prevention survey cited in the reporting, the overwhelming majority of middle and high school students who use e-cigarettes prefer fruit and candy-flavored products. Those concerns helped drive previous FDA efforts to restrict flavored vaping products and formed the basis for arguments that easing restrictions could contribute to increased youth nicotine use.
Supporters of the administration’s approach point to a different public health argument. Some research has suggested that vaping products may help adult smokers transition away from combustible cigarettes, which remain one of the leading causes of preventable death in the United States. Defending the administration’s decision, White House spokesperson Kush Desai rejected suggestions that political contributions played any role in shaping policy. “The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Desai said. He further argued that the FDA’s treatment of vaping products and nicotine pouches was rooted in “recent evidence that has found they can help adults quit smoking.”
The new guidance nevertheless sparked reported disagreement inside the administration itself. According to accounts from individuals familiar with internal discussions, Makary had expressed reservations about changing the FDA’s position because of concerns regarding the impact flavored nicotine products could have on children and adolescents. Those concerns reportedly intensified after the Florida meeting with tobacco executives and the subsequent pressure surrounding the agency’s regulatory approach. Four days after the FDA announced the new guidance, Makary resigned. According to reporting cited in the source material, he told associates that he could not in good conscience continue leading an agency that supported the policy. Rich Danker, Kennedy’s chief spokesperson, also reportedly departed over disagreements tied to the vaping policy change.
The FDA action also bypassed the agency’s traditional rule-making process, an aspect of the decision that has drawn additional scrutiny. While the guidance included a commitment to prioritize enforcement against illegal foreign-made vaping products, particularly imports from China, critics questioned why such a significant policy shift was implemented through guidance rather than the more extensive public review procedures typically associated with major regulatory changes. The vaping market is estimated to be worth approximately $6 billion, making decisions affecting product approvals and market access financially significant for manufacturers seeking to expand their share of the industry.
The administration’s vape decision did not emerge in isolation. Since returning to office, Trump has taken several actions welcomed by tobacco companies. On his second full day in office, his administration withdrew a proposed federal ban on menthol cigarettes. The administration also abandoned a Biden-era initiative that would have sharply reduced nicotine levels in cigarettes. During the 2024 campaign, Trump openly pledged to “save vaping,” a position that distinguished him from some public health advocates who supported stricter nicotine regulations. Financial records show that tobacco and vaping interests responded favorably. Trump’s inaugural committee reportedly received more than $3 million from vaping-related donors, including $1.25 million from the Vapor Technology Association and $1 million each from Altria and Breeze Smoke.
MAGA Inc. has defended its acceptance of tobacco-industry contributions. Spokesperson Alex Pfeiffer said the organization “is pleased to accept legal contributions from those who agree with President Trump’s America First agenda and his goal to make America great again.” Reynolds did not respond to requests for comment regarding the donation or the subsequent policy developments. Campaign finance filings show that the tobacco company was not alone in supporting the super PAC. During the same reporting period, MAGA Inc. also received million-dollar contributions from a division of private prison giant Geo Group, Republican donor Marlene Ricketts, and other major contributors.
For critics, however, the issue extends beyond a single campaign donation or one regulatory decision. The vaping controversy has become part of a broader debate over whether wealthy corporate interests are receiving privileged access to policymakers and obtaining favorable outcomes after making substantial political contributions. The criticism has been particularly pointed because Kennedy entered office promoting a “Make America Healthy Again” agenda that promised to reduce corporate influence over public health decisions. Opponents of the FDA’s new guidance argue that the sequence of donations, lobbying access, presidential intervention, and regulatory change raises questions about whether that commitment has been upheld.
Among the administration’s critics is Rep. Seth Magaziner of Rhode Island, who pointed to the apparent contradiction between the administration’s health-focused rhetoric and its actions regarding tobacco regulation. Summarizing what opponents see as the central issue raised by the episode, Magaziner said, “In the Trump administration, money beats MAHA every time.”
COMMENTS